It’s not a competition but Kite’s CAR-T therapy just claimed a first in Europe
As Novartis awaits a final FDA ruling on its CAR-T therapy, Santa Monica, California-based Kite Pharma has jumped the Atlantic to file the first Marketing Authorization Application MAA with the European Medicines Agency EMA. Announced Monday, the MAA centers around axicabtagene ciloleucel axi-cel, a chimeric antigen receptor CAR T-cell therapy that targets CD19, a protein expressed on the surface of the B-cells that drive lymphomas and leukemias